Live Breaking News & Updates on Nikita sashdev

Stay informed with the latest breaking news from Nikita sashdev on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nikita sashdev and stay connected to the pulse of your community

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Tenerife , Andalucísp , Spain , United-states , United-kingdom , Vancouver , British-columbia , Canada , Frankfurt , Brandenburg , Germany , Madrid

BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction...

United-states , Canada , United-kingdom , France , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , British , Canadian , Nikita-sashdev

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton,...

Indiana , United-states , Canada , United-kingdom , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , America , British , Canadian

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:

South-africa , United-states , Canada , United-kingdom , Brazil , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , Canadian , Brazilian

BioVaxys Announces Appointment To Its Scientific Advisory Board

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology...

New-york , United-states , Canada , United-kingdom , Vancouver , British-columbia , Congo , Frankfurt , Brandenburg , Germany , British , Canadian

BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF
) ("BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term Sheet") with BioElpida S.A.S. ("BioElpida") of Lyon, France, to collaborate on the build-out for the clinical-grade manufacturing process and aseptic packaging for BXV-0918A, BioVaxys' vaccine for Stage III/Stage IV ovarian cancer. Completion of the GMP-grade bioproduction process development is planned for later this year, with the EU Phase I/II clinical trial slated for early 2022, pending European Medicines Agency ("EMEA") approval.
BioElpida is a biotechnology contract development and manufacturing company ("CDMO") which applies single-use bioprocessing for development and manufacturing of biological and cell-based products. BioElpida's expertise extends from R&D to pharmaceutical manufacturing and release of clinical batches, and intermediate steps such as process development, feasibility studies, analytical method validation, as well as aseptic fill & finish and other bioproduction services. BioElpida's facility is certified for clinical bioproduction by France's National Security Agency of Medicines and Health Products (ANSM).

United-states , Canada , United-kingdom , Spain , France , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , America , Canadian

BioVaxys Announces Appointment of Corporate Advisor

BioVaxys Announces Appointment of Corporate Advisor
News provided by
Share this article
VANCOUVER, BC, Feb. 12, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (
CSE: BIOV) (FRA: 5LB) ("BioVaxys" or "the Company") is pleased to announce that is has appointed Shmuel Farhi as Corporate Advisor to the Company. Mr. Farhi, founder and President of Farhi Holding Corporation, a company that owns more than four million square feet of properties across Ontario, Canada, is a prolific investor in the Canadian, American, and Israeli biotech industry.
James Passin, CEO of BioVaxys, stated, "BioVaxys is delighted to onboard the legendary billionaire developer, philanthropist, and biotech financier, Shmuel Farhi, as Corporate Advisor. We look forward to leveraging the deep business expertise of Shmuel, who is now one of BioVaxys's largest shareholders, as we continue to advance the clinical and commercial development of BVX-0320, BVX-0918A, and COVID-T™."

United-states , United-kingdom , Canada , Israel , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , Israeli , Canadian , American

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Features Observation Of Neutralizing Antibodies To SARS-CoV-2
Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging SARS-CoV-2 Strains
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)
("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union ("EU") for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization ("CMO") and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application ("CTA") for BVX-0918A with the European Medicines Agency ("EMEA") later this year.

United-states , South-africa , Canada , United-kingdom , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , Canadian , South-african , American

Financial News Media | BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program and Vaccine Platform Expansion

Vancouver, BC – January 25, 2021 –
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union (“EU”) for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization (“CMO”) and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application (“CTA”) for BVX-0918A with the European Medicines Agency (“EMEA”) later this year.

United-states , South-africa , Canada , United-kingdom , Vancouver , British-columbia , Frankfurt , Brandenburg , Germany , Canadian , South-african , American